Cancer diagnosis technology company, Flash Tissue Diagnostics, aims for a leap in cancer diagnostics

Flash Tissue Diagnostics Revolutionizes Cancer Diagnostics

In the heart of Munich, a city renowned for its vibrant life science scene, a new startup named Flash Tissue Diagnostics is making waves in the field of cancer diagnostics. Founded in July 2024 by Dr. Karim Tabiti, Prof. Axel Behrens, and Dr. Hendrik Messal, the company aims to revolutionize tissue analysis in pathology with its proprietary flash technology.

The founders' approach combines controlled risk with scientific substantiation, relying on hard data, validated methods, and clear goals. They envision clinically approved diagnostic solutions based on Flash technology in use in pathology departments and cancer centers worldwide within five years.

The flash method is crucial in cancer diagnostics, such as sentinel lymph node analysis. Previous methods of tissue analysis are two-dimensional, time-consuming, and limited in their informative value. Flash Tissue Diagnostics aims to take diagnostics to a new level - faster, more precise, and three-dimensional.

One of the key challenges faced by Flash Tissue Diagnostics is transitioning from research to clinical application. However, the founders are undeterred. They bring over 25 years of experience in the diagnostics industry to the table, with Dr. Karim Tabiti joining as CEO.

Diagnostics involves human lives, requiring a sense of responsibility, structure, and quality, as well as the courage to innovate. The founders are well-aware of this, and they strive to make a measurable contribution to increasing cancer survival rates through earlier and more precise diagnoses.

The scientific basis of Flash was published in Nature in 2019 by the founders themselves. Since its inception, the company has launched its first product, an RUO kit for organoid detection, just one year after its founding.

Munich offers ideal conditions for life science startups, with a strong research landscape, excellent infrastructure, access to talent, and proximity to industry. The network in Munich, including incubators like MAXL, Baystartup, and UnternehmerTUM, helps drive medical innovation.

The founders aim to establish the Flash system in leading research laboratories worldwide, particularly in the field of 3D spatial biology and cancer modeling, within one year. They have experienced Munich as a startup location as one that offers a combination of scientific excellence and entrepreneurial support.

In five years, the founders aim to offer clinically approved diagnostic solutions based on Flash technology, which will be used in pathology departments and cancer centers worldwide. With its cutting-edge technology and dedicated team, Flash Tissue Diagnostics is poised to redefine the future of cancer diagnostics.